# What Kills Biotech Investments: The Biggest Risks, Quantified > Clinical failure, regulatory rejection, and capital exhaustion destroy the majority of biotech investments before they return a dollar. This explainer quantifies each risk, shows exactly where to find the warning signs, and gives you a repeatable due-diligence checklist. ## What Is the Single Biggest Risk That Kills Biotech Investments? Clinical failure is the leading killer of biotech value. Across all therapeutic areas, roughly 90 percent of drug candidates that enter Phase 1 trials never reach approval. Phase 2 is the graveyard: historical success rates sit near 30 to 40 percent for the Phase 2-to-Phase 3 transition, and for oncology the number drops below 25 percent. A single top-line readout on a pivotal trial can erase 60 to 90 percent of a company's market cap in a single session. Every other risk category is secondary to this one, but together they compound in ways that trap even experienced investors. ## How Often Does the FDA Reject or Delay Approval? Regulatory rejection is the second-largest discrete risk event. The FDA issues Complete Response Letters (CRLs) to a meaningful share of New Drug Applications (NDAs) and Biologics License Applications (BLAs) on the first submission cycle. Industry analyses from FDA performance data suggest the first-cycle approval rate for standard review applications has ranged between 50 and 70 percent depending on the year and therapeutic category. Priority Review and Breakthrough Therapy designation improve those odds but do not guarantee approval. The FDA's publicly accessible Drugs@FDA database and the CDER approval statistics page (accessible at fda.gov/drugs/drug-approvals-and-databases) let you look up every CRL issued for a given drug class, giving you a base rate before you model your investment thesis. Specific red flags to check on FDA.gov and the company's SEC filings: - Outstanding Complete Response Letters from prior submissions - Clinical holds listed on ClinicalTrials.gov under the NCT record - Advisory Committee (AdCom) votes that were non-favorable, which appear in FDA briefing documents - Manufacturing deficiencies cited in FDA Form 483 observations (requested via FOIA or sometimes disclosed in 10-K risk factors) ## What Does Capital Exhaustion Look Like Before It Happens? The third killer is running out of money before a catalyst. A biotech with less than 12 months of cash runway at current burn rate is in distress territory, and runway under 18 months should trigger heightened scrutiny. You can calculate this directly from quarterly SEC filings on EDGAR (sec.gov/edgar): take the cash and equivalents line from the balance sheet, then divide by the quarterly operating cash outflow from the cash flow statement. Multiply by three to convert to months. When runway tightens, companies raise capital through dilutive at-the-money equity offerings, convertible notes, or licensing deals that surrender future royalty economics. The SEC requires disclosure of material financing events in 8-K filings within four business days. Checking a company's 8-K history on EDGAR for the phrase "sales agreement" or "purchase agreement" reveals whether dilutive shelf offerings are already in motion. ## How Much Does Patent Expiry and IP Risk Matter? For late-stage and commercial biotechs, intellectual property erosion is a quantifiable threat. A compound facing a patent cliff within three to five years of peak revenue will see generic or biosimilar entry compress margins by 80 to 90 percent within 24 months of exclusivity loss, based on historical erosion curves from established biologics markets. You can map the precise patent landscape using the USPTO Patent Full-Text Database (patents.google.com or patft.uspto.gov) and cross-reference with the FDA Orange Book (for small molecules) or Purple Book (for biologics) to identify which patents are actually listed and when they expire. Key patent risks to quantify: - Composition-of-matter patent expiry date versus projected commercialization timeline - Active Inter Partes Review (IPR) petitions filed at the USPTO Patent Trial and Appeal Board (ptab.uspto.gov) - Freedom-to-operate gaps if a competitor holds blocking patents on a formulation or delivery method ## What Does the Scientific Literature Reveal That Management Does Not? PubMed (pubmed.ncbi.nlm.nih.gov) is a free, underused primary source. Before any late-stage readout, search for independent replication studies of the drug's mechanism of action. If a mechanism has generated reproducible results only from the sponsor's own labs, that is a scientific replication risk that the investor presentation will never name explicitly. Biomarker endpoint selection is another hidden risk: trials that use surrogate endpoints (tumor shrinkage, biomarker levels) instead of overall survival face a higher probability of FDA skepticism at the NDA stage. ## What Is the Competitive Obsolescence Risk and How Do You Screen for It? A drug can succeed in every clinical and regulatory step and still be commercially irrelevant if a faster competitor gains approval first or achieves superior efficacy data. ClinicalTrials.gov allows a structured search by condition, intervention type, and phase to map the full competitive landscape before a company's data readout. A target indication with six or more Phase 3 competitors is a saturated pipeline; pricing power and reimbursement access will be contested from day one. ## Due Diligence Checklist: The Seven Questions That Catch Killers Early 1. What is the Phase 2 historical success rate in this exact indication? (Source: ClinicalTrials.gov + published meta-analyses on PubMed) 2. Does the company have less than 18 months of runway? (Source: SEC EDGAR 10-Q, most recent quarter) 3. Has the FDA issued prior CRLs for this drug or a close analogue? (Source: Drugs@FDA, FDA press releases) 4. Are there active IPR petitions against core patents? (Source: ptab.uspto.gov) 5. Does the trial use a surrogate endpoint that FDA has previously questioned in this therapeutic class? (Source: FDA guidance documents, AdCom transcripts) 6. How many Phase 3 competitors are in the same indication? (Source: ClinicalTrials.gov advanced search) 7. Has management disclosed any material financing agreements in recent 8-Ks that signal dilution ahead? (Source: SEC EDGAR 8-K filings) ## How Can You Run This Analysis Faster Without Missing Primary Sources? Manually cross-referencing FDA, SEC EDGAR, ClinicalTrials.gov, USPTO, and PubMed for a single company takes four to eight hours if done rigorously. MedFuel Intel automates this process with AI-driven due-diligence reports that pull live data from each primary source, flag clinical, regulatory, financial, and IP risks in a single structured output, and verify every claim against its original document. Run a free Red Flag Screener on any biotech in your watchlist at https://medfuelintel.com and get a prioritized risk summary in minutes rather than hours. --- Informational only, not investment advice. --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/what-kills-biotech-investments-the-biggest-risks-quantified). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.